Primary Pharmacology of CB213, a LAG-3-PD1 Co-targeting Humabody™

Time: 2:00 pm
day: Day One


  • CB213 is engineered to engage LAG-3 particularly on PD1 expressing cells
  • Human ex vivo and mouse syngeneic in vivo studies illustrate CB213 anti-tumor activity
  • Pharmacokinetics studies in non-human primates suggest weekly or biweekly clinical dosing of CB213